Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...
Technology Networks spoke with Dr. Thomas Dennison, University of Cambridge, to learn more about the advantages of using ...
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...
US genetic medicines company Scribe, which is seeking to unlock the potential of CRISPR to transform human health, announced ...
In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Intellia Therapeutics (NTLA – Research ...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
Technological advancements, particularly in gene editing techniques such as CRISPR-Cas9, have significantly enhanced the precision and efficiency of gene therapy approaches. Moreover, increased ...
Security was tight for the first day of the J.P. Morgan Healthcare Conference, which featured two deals involving privately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback